Not Yet RecruitingNot Applicable

Clonal Hematopoiesis of Immunological Significance

France5,000 participantsStarted 2026-04

Plain-language summary

Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \>=18 years old; * Confirmed dysimmune manifestations: clinical or biological abnormality or systemic disease; * Presence or absence of myeloid or lymphoid blood disease according to World Health Organization (WHO) classification Exclusion Criteria: * Persons benefiting from special protection: adults under guardianship and curatorship; * People hospitalized without their consent and not protected by law; persons deprived of liberty; * Persons not affiliated to the social security system

What they're measuring

Incidence of dysimmune manifestations associated with hematological disorders

Timeframe: Baseline

Trial details

NCT IDNCT05969821

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2036-04

Contact for this trial

Arsene MEKINIAN, MD PhD

+33149282392 arsene.mekinian@aphp.fr

View on ClinicalTrials.gov More Immune System Diseases trials